TY - JOUR
T1 - Laboratory evaluation of SARS-CoV-2 in the COVID-19 pandemic
AU - Parikh, Bijal A.
AU - Farnsworth, Christopher W.
N1 - Funding Information:
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Christopher receives unrelated research funding from Beckman Coulter, Abbott Diagnostics, NowDiagnostics, and Siemens Healthineers. He has also served as an advisor for Roche Diagnostics within the past year.
Funding Information:
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Christopher receives unrelated research funding from Beckman Coulter , Abbott Diagnostics , NowDiagnostics , and Siemens Healthineers . He has also served as an advisor for Roche Diagnostics within the past year.
Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/3
Y1 - 2021/3
N2 - Laboratory evaluation of SARS-CoV-2 involves the detection of viral nucleic acid, viral protein antigens, and the antibody response. Molecular detection of SARS-CoV-2 is the only diagnostic test currently available in acutely or recently infected individuals. In contrast, serological testing is typically performed once viral RNA has been cleared and symptoms have resolved. This leads to some confusion among clinicians as to which test to order and when each is appropriate. While SARS-CoV-2 assays can suffer from poor sensitivity, all FDA authorized assays to date are intended to be qualitative. Serological tests have multiple assay formats, detect various classes of immunoglobulins, and have a distinct role in seroprevalence studies; however, the association with long-term protection remains unclear. Both molecular and serological testing for SARS-CoV-2 have complementary roles in patient management, and we highlight the challenges faced by clinicians and laboratorians alike in the evaluation and interpretation of the currently available laboratory assays.
AB - Laboratory evaluation of SARS-CoV-2 involves the detection of viral nucleic acid, viral protein antigens, and the antibody response. Molecular detection of SARS-CoV-2 is the only diagnostic test currently available in acutely or recently infected individuals. In contrast, serological testing is typically performed once viral RNA has been cleared and symptoms have resolved. This leads to some confusion among clinicians as to which test to order and when each is appropriate. While SARS-CoV-2 assays can suffer from poor sensitivity, all FDA authorized assays to date are intended to be qualitative. Serological tests have multiple assay formats, detect various classes of immunoglobulins, and have a distinct role in seroprevalence studies; however, the association with long-term protection remains unclear. Both molecular and serological testing for SARS-CoV-2 have complementary roles in patient management, and we highlight the challenges faced by clinicians and laboratorians alike in the evaluation and interpretation of the currently available laboratory assays.
KW - Analytical sensitivity
KW - COVID-19
KW - Clinical sensitivity
KW - Molecular diagnostics
KW - SARS-CoV-2
KW - Serology
UR - http://www.scopus.com/inward/record.url?scp=85100051892&partnerID=8YFLogxK
U2 - 10.1016/j.berh.2021.101660
DO - 10.1016/j.berh.2021.101660
M3 - Review article
C2 - 33518410
AN - SCOPUS:85100051892
SN - 1521-6942
VL - 35
JO - Best Practice and Research: Clinical Rheumatology
JF - Best Practice and Research: Clinical Rheumatology
IS - 1
M1 - 101660
ER -